Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Chief Informatics Officer | February 15, 2022 | February 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date February 15, 2022 · Filed February 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2032-02-14 | Direct | 550,000 |
Reported balance
After 2022-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-15 · Grant · Acquired 550,000 · Balance 550,000 F1: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 16, 2022 02:10 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-22-010057 · doc4.xml · derivative · entry 1 Shams Soheil · CIK 0001888376 · Chief Informatics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| December 30, 2021 Filed Feb 11, 2022 23:05 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GiftCommon Stock | 318,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008977 · doc5.xml · nonDerivative · entry 1 Shams Soheil · CIK 0001888376 · Chief Informatics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,006,479 Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:08 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001209191-21-062493 · doc4.xml · derivative · entry 1 Shams Soheil · CIK 0001888376 · Chief Informatics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on October 18, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from October 18, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan) through each such applicable vesting date and the terms of the Company's 2020 Inducement Plan. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 21:56 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 5,325,378 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-061176 · doc4.xml · nonDerivative · entry 1 Shams Soheil · CIK 0001888376 · Chief Informatics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,325,378 F1 · shares: Of which 5,006,479 shares (the "Restricted Shares") are subject to a Stock Restriction Agreement, dated October 8, 2021, by and between the Issuer and Soheil Shams (the Restriction Agreement") and vest as follows: one-third of the Restricted Shares will vest on October 18, 2022 and one-twelfth of the Restricted Shares shall vest every three months following October 18, 2022, in each case subject to Dr. Shams' continuous Service (as defined in the Restriction Agreement). The number of shares that vest upon each vesting date shall be rounded down to the nearest whole share, with the balance of any shares that did not vest as a result of such rounding to vest on the final vesting date, subject to rounding. The unvested shares are subject to adjustment pursuant to the terms of the Merger Agreement (as defined below) and accelerate upon a termination in Service, subject to certain conditions. F2 · price: On October 18, 2021, the Issuer completed its previously announced acquisition (the "Acquisition") of BioDiscovery, Inc. ("BioDiscovery"), as contemplated by that certain Agreement and Plan of Merger, dated as of October 8, 2021 (the "Merger Agreement"), by and among the Issuer, Starship Merger Sub I, Inc., Starship Merger Sub II, LLC, BioDiscovery and Soheil Shams, solely in his capacity as the securityholders' representative. Pursuant to the Acquisition, all outstanding shares of BioDiscovery common stock, no par value, held by Dr. Shams were automatically cancelled and converted into the right to receive (i) cash consideration and (ii) shares of Issuer common stock, $0.0001 par value per share, as specified in the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.